Rosen Quoted on FDA Warning Letters Issued to Drug Compounders
January 31, 2014
Inside Health Policy
Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.” The article discusses the two warning letters issued by the FDA to drug compounders in recent weeks chastising them for lacking patient-specific prescriptions. Rosen was quoted saying, “If you do not have an individual prescription for every patient for whom you compound, this is one way FDA is sending the message that you are not compliant with 503A at this time.”
People
Related News
June 20, 2025
In the News
Brian Wheeler and Lyman Thai Comment on Private Equity's Entry into Niche Sports
Foley & Lardner LLP partners Brian Wheeler and Lyman Thai described private equity's growing investments in niche sports in the Pensions & Investments article, "Ares Management buys minority stake in French sailing team."
June 16, 2025
In the News
Gregory Husisian on Customs Compliance Violations – 'It's a sharply increased risk profile'
Foley & Lardner LLP partner Gregory Husisian joined the SupplyChainBrain Thought Leaders episode, "Getting Ahead of Customs Compliance Violations," to describe the heightened risk environment importers face under the current trade and regulatory regime.
June 11, 2025
In the News
Foley Named Top US Firm for IP Lateral Hires by ManagingIP
Foley & Lardner LLP was named the top United States firm for intellectual property lateral partner hires in April and May 2025 based on data from ManagingIP's Talent Tracker.